BURLINGTON, Ontario--(BUSINESS WIRE)--$ANRG #ANRG--Anaergia Inc. (“Anaergia” or the “Company”) (TSX: ANRG) today announced its financial results for the three- and nine-month periods ended September 30, 2023 (“Q3 2023”), and the related manage
Encouraging preliminary data from the ongoing DIPG clinical study to be presented at the 2023 Society for Neuro-Oncology Annual Meeting in VancouverOAKLAND, Calif.--(BUSINESS WIRE)--SonALAsense, a pioneer in the development of non-invasive Sonodynamic Th
Vasomune Therapeutics and AnGes drug candidate AV-001 Receives Positive Recommendation from the IDSMB for AV001-004 Phase 2a StudyTORONTO--(BUSINESS WIRE)--#ARDS--Vasomune Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the deve
Poultry industry leaders unite over industry principles to reduce the need to use antimicrobials in an effort to combat antimicrobial resistanceMINNEAPOLIS--(BUSINESS WIRE)--Antibiotics used to treat bacterial infections can contribute to antimicrobial r
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic
- Announced unprecedented positive Phase 2 interim data for CYB003, its proprietary deuterated psilocybin analog, in major depressive disorder - - Announced closing of a unit offering of up to US$64 (C$88.4) million led by one of its largest institutiona
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Company’s collaboration partner, Otsuka Pharmaceutical Ltd., filed a new drug application (NDA) for voclos
BURLINGTON, Ontario--(BUSINESS WIRE)--Anaergia Inc. (“Anaergia” or the “Company”) (TSX: ANRG) will release financial results for the third quarter of 2023 prior to market open on Tuesday, November 14, 2023. Conference Call and Webcast Details A co
- Completed successful PK/PD study for otenaproxesul’s new formulation - Phase II initiation on track for upcoming quarter - Ended quarter with $28 million in cash and equivalentsTORONTO--(BUSINESS WIRE)--$ATBPF--Antibe Therapeutics Inc. (TSX: ATE, OTC
Credit Facility provides immediate access to a new $3.5 million revolving credit facility Strengthened balance sheet and borrowing capacity to support accelerated growth strategy Improved cash flows resulting from re-financing of existing HealthPointe
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.